Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Merck's Topline Data From Phase 3 LITESPARK-022 Trial Of Keytruda (Pembrolizumab) Plus Welireg (Belzutifan) In Adjuvant Setting Showed Statistically Significant And Clinically Meaningful Improvement In Disease-free Survival For Clear Cell Renal Cell Carcinoma

Author: Benzinga Newsdesk | October 28, 2025 05:48am

First combination regimen to demonstrate improvement in DFS compared to KEYTRUDA monotherapy for these patients in the adjuvant setting
LITESPARK-022 is the second positive Phase 3 study for WELIREG as part of a combination regimen in RCC

Posted In: MRK